Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Leukemia
    March 2026
  1. BARRAL L, Lespinasse N, Martin Cardozo C, Jeanpierre S, et al
    Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance.
    Leukemia. 2026 Mar 18. doi: 10.1038/s41375-026-02904.
    >> Share

  2. WOBST J, Ruge H, Senk S, Muller H, et al
    Multiple myeloma with concomitant chronic lymphocytic leukemia: evidence for independent clonal origin.
    Leukemia. 2026 Mar 18. doi: 10.1038/s41375-026-02918.
    >> Share

  3. PARKER H, Carr L, Norris K, Nilsson-Takeuchi A, et al
    High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.
    Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02906.
    >> Share

  4. LOGHAVI S, Farhat A, Jamison TJ, El Hajjar G, et al
    Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
    Leukemia. 2026 Mar 11. doi: 10.1038/s41375-026-02905.
    >> Share

  5. SELIMOGLU-BUET D, Chevret S, Santini V, Thepot S, et al
    Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?
    Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02901.
    >> Share

  6. SMALLBONE P, Cao K, Saliba RM, Carmarzzi Y, et al
    Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.
    Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02907.
    >> Share

  7. ZHANG L, Han Q, Xiang H, Lapalombella R, et al
    Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02898.
    >> Share

  8. SETIAWAN T, Muhammad JA, Julianto NM, Wirawan LM, et al
    Correction: Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
    Leukemia. 2026 Mar 5. doi: 10.1038/s41375-026-02909.
    >> Share

  9. TIONG IS, Hunter S, Kankanige Y, Mehta NN, et al
    Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets.
    Leukemia. 2026;40:649-660.
    >> Share

  10. GUO Y, Sui P, Yang H, Zhu G, et al
    Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.
    Leukemia. 2026;40:594-608.
    >> Share

  11. SOBERON V, Osswald L, Moore A, Sosnowska D, et al
    Strong constitutive NF-kappaB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.
    Leukemia. 2026;40:522-539.
    >> Share

  12. CAMIOLO G, Gonzalez Silvera D, Leah T, Schwaller J, et al
    CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.
    Leukemia. 2026;40:540-552.
    >> Share

  13. CHONABAYASHI K, Iwasaki M, Kanda J, Takamori H, et al
    NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.
    Leukemia. 2026;40:491-501.
    >> Share

    February 2026
  14. BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
    Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia.
    Leukemia. 2026 Feb 25. doi: 10.1038/s41375-026-02897.
    >> Share

  15. LECORNEC N, Rabian F, Dourthe ME, Chevillon F, et al
    Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Feb 24. doi: 10.1038/s41375-026-02867.
    >> Share

  16. LAUSEKER M, Sacha T, Klamova H, Yakoleva J, et al
    Development of a prognostic scoring system for chronic myeloid leukemia in blast phase.
    Leukemia. 2026 Feb 19. doi: 10.1038/s41375-026-02875.
    >> Share

  17. WANG C, Ge S, Gao J, Yang R, et al
    The fragile equilibrium of cancer latency: lessons from spontaneous remission in congenital leukemia.
    Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02888.
    >> Share

  18. CHAKRABORTY S, Morganti C, Zaldana K, Rivera Pena B, et al
    A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
    Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02883.
    >> Share

  19. NIELSEN CG, Als-Nielsen B, Albertsen BK, Davidsson OB, et al
    Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study.
    Leukemia. 2026 Feb 10. doi: 10.1038/s41375-026-02873.
    >> Share

  20. MECKLENBRAUCK R, Villaverde Ramiro A, Strang E, Gabdoulline R, et al
    Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.
    Leukemia. 2026 Feb 9. doi: 10.1038/s41375-026-02874.
    >> Share

  21. BIRDWELL CE, Fiskus W, Mill CP, Kadia TM, et al
    BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
    Leukemia. 2026;40:304-313.
    >> Share

  22. FULLIN J, Topcu E, Zielinska KA, Schimmer RR, et al
    The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.
    Leukemia. 2026;40:279-292.
    >> Share

    January 2026
  23. OEHLER VG, Sala-Torra O, Gilderman N, Beppu L, et al
    Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
    Leukemia. 2026 Jan 23. doi: 10.1038/s41375-025-02852.
    >> Share

  24. WANG Y, Wang X, Li M, Song H, et al
    Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.
    Leukemia. 2026 Jan 22. doi: 10.1038/s41375-026-02862.
    >> Share

  25. ANSUINELLI M, Peragine N, De Propris MS, Puzzolo MC, et al
    Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.
    Leukemia. 2026 Jan 22. doi: 10.1038/s41375-025-02855.
    >> Share

  26. REA D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, et al
    Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
    Leukemia. 2026 Jan 19. doi: 10.1038/s41375-025-02847.
    >> Share

  27. HERNANDEZ-SANCHEZ A, Villaverde Ramiro A, Strang E, Turki AT, et al
    Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.
    Leukemia. 2026 Jan 14. doi: 10.1038/s41375-025-02851.
    >> Share

  28. BURCHERT A, Nicolini FE, le Coutre P, Saussele S, et al
    Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
    Leukemia. 2026 Jan 12. doi: 10.1038/s41375-025-02859.
    >> Share

  29. GONZALES F, Schneider C, Alexe G, Lin S, et al
    Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.
    Leukemia. 2026 Jan 8. doi: 10.1038/s41375-025-02845.
    >> Share

  30. AGATHANGELIDIS A, Iatrou A, Pechlivanis N, Karakatsoulis G, et al
    Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02797.
    >> Share

  31. AYOUB M, Hitier C, Dehgane L, Mallet E, et al
    Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02846.
    >> Share

  32. FUJIMOTO A, Maeda T, Doki N, Fukuhara N, et al
    Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
    Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02854.
    >> Share

  33. GURNARI C, Makishima H, Durmaz A, Attardi E, et al
    DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
    Leukemia. 2026;40:178-187.
    >> Share

  34. BILL M, Eckardt JN, Dohner K, Rohnert MA, et al
    Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
    Leukemia. 2026;40:63-71.
    >> Share

    December 2025
  35. YANG Y, Liu X, Wei J, Qin J, et al
    In vivo expression of CD3/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)/PD-L1(+) leukemia.
    Leukemia. 2025 Dec 23. doi: 10.1038/s41375-025-02832.
    >> Share

  36. DINH TTT, Lordo MR, Zhang AY, Goda C, et al
    Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.
    Leukemia. 2025 Dec 22. doi: 10.1038/s41375-025-02829.
    >> Share

  37. HO TC, LaMere MW, Kawano H, Byun DK, et al
    Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02816.
    >> Share

  38. ERNST P, Lohse C, Lauseker M, Geissler J, et al
    Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02826.
    >> Share

  39. FEDENKO A, Czapinska H, Kramer A, Stolzel F, et al
    Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02835.
    >> Share

  40. STRUCKMAN NE, Koutsoumpli G, de Jong RCM, van der Lee DI, et al
    A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.
    Leukemia. 2025 Dec 12. doi: 10.1038/s41375-025-02817.
    >> Share

  41. DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
    Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
    Leukemia. 2025 Dec 10. doi: 10.1038/s41375-025-02827.
    >> Share

  42. HAAKSMA LH, Palmieri R, Reuvekamp T, Tettero JM, et al
    Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.
    Leukemia. 2025 Dec 10. doi: 10.1038/s41375-025-02825.
    >> Share

  43. DEHGANE L, Mallet E, Brasseur C, Krzisch D, et al
    REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.
    Leukemia. 2025 Dec 9. doi: 10.1038/s41375-025-02818.
    >> Share

  44. HOCHHAUS A, Gale RP
    40 years of LEUKEMIA.
    Leukemia. 2025 Dec 8. doi: 10.1038/s41375-025-02840.
    >> Share

  45. MIKKELSEN T, Helenius M, Ampatzidou M, Attarbaschi A, et al
    Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.
    Leukemia. 2025 Dec 8. doi: 10.1038/s41375-025-02804.
    >> Share

  46. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Dec 2. doi: 10.1038/s41375-025-02824.
    >> Share

  47. KADIRKAMANATHAN R, Georgiadis C, Kloos A, Joshi A, et al
    Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.
    Leukemia. 2025;39:2978-2987.
    >> Share

  48. ELEFTHERIOU M, Russell J, Tzelepis K
    Epitranscriptomic advances in normal and malignant hematopoiesis.
    Leukemia. 2025;39:2848-2857.
    >> Share

  49. PURHONEN M, Tatun M, Luukkainen K, Hung K, et al
    Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.
    Leukemia. 2025;39:2968-2977.
    >> Share

  50. KARAKASLAR EO, Argiro EM, Struckman NE, Shirali Hz R, et al
    Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.
    Leukemia. 2025;39:2916-2925.
    >> Share

  51. BAKEWELL J, Moorman AV, Ryan SL
    DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.
    Leukemia. 2025;39:2835-2847.
    >> Share

  52. MIRAKI-MOUD F, Ariza-McNaughton L, KoKo T, Othman J, et al
    Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
    Leukemia. 2025;39:2895-2906.
    >> Share

    November 2025
  53. CASTAGNETTI F, Breccia M, Abruzzese E, Bassan R, et al
    Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.
    Leukemia. 2025 Nov 18. doi: 10.1038/s41375-025-02796.
    >> Share

  54. SUI P, Li Y, Hong J, Delma CR, et al
    Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.
    Leukemia. 2025 Nov 17. doi: 10.1038/s41375-025-02803.
    >> Share

  55. LOCATELLI F, Rizzari C, Gruhn B, Klingebiel T, et al
    Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.
    Leukemia. 2025 Nov 13. doi: 10.1038/s41375-025-02800.
    >> Share

  56. ZHENG H, Zhang L, Li L
    Correspondence to "Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis".
    Leukemia. 2025 Nov 12. doi: 10.1038/s41375-025-02812.
    >> Share

  57. DHIR A, Ethell A, Watkins R, Lam C, et al
    The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.
    Leukemia. 2025 Nov 10. doi: 10.1038/s41375-025-02799.
    >> Share

  58. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Nov 3. doi: 10.1038/s41375-025-02793.
    >> Share

  59. OHLSTROM D, Bakhtiari M, Mumme H, Michaud M, et al
    Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.
    Leukemia. 2025;39:2721-2734.
    >> Share

  60. ZAZA A, Zardo G, Banella C, Tucci S, et al
    PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias.
    Leukemia. 2025;39:2708-2720.
    >> Share

  61. PATEL SA, Bennett JM
    The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.
    Leukemia. 2025;39:2603-2609.
    >> Share

  62. ZIMOLOVA V, Burocziova M, Berkova L, Grusanovic S, et al
    Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.
    Leukemia. 2025;39:2745-2757.
    >> Share

    October 2025
  63. GREINER J, Schuler PJ, Schrezenmeier H, Weiss J, et al
    Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.
    Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02764.
    >> Share

  64. NIKKILA A, Lohi O, Abrahamsson J, Griskevicius L, et al
    Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.
    Leukemia. 2025 Oct 27. doi: 10.1038/s41375-025-02789.
    >> Share

  65. VU TT, Stolzel F, Wang KW, Rollig C, et al
    Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
    Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02788.
    >> Share

  66. GOODMAN SJ, Butcher DT, Guger SL, Diehl E, et al
    DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.
    Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02779.
    >> Share

  67. GEELS J, van Rhenen A, Gradowska P, Asselbergs FW, et al
    Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.
    Leukemia. 2025 Oct 10. doi: 10.1038/s41375-025-02753.
    >> Share

  68. VOSS RK, Pastor Loyola VB, Cardenas MF, Kumar P, et al
    Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02774.
    >> Share

  69. HUND I, Hess ME, Andrieux G, Stomper J, et al
    Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02780.
    >> Share

  70. TAMAI H, Miyake K, Miyake N, Asano J, et al
    Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Oct 6. doi: 10.1038/s41375-025-02782.
    >> Share

  71. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Oct 2. doi: 10.1038/s41375-025-02778.
    >> Share

  72. SETIAWAN T, Muhammad JA, Marcellina N, Wirawan LM, et al
    Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
    Leukemia. 2025 Oct 1. doi: 10.1038/s41375-025-02768.
    >> Share

  73. SMITH C, Charbonnier G, Simonin M, Balducci E, et al
    Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).
    Leukemia. 2025;39:2344-2354.
    >> Share

  74. KAPAHNKE K, Plenge T, Klaus T, Gupta MK, et al
    The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.
    Leukemia. 2025;39:2406-2418.
    >> Share

  75. PEREZ-AMILL L, Armand-Ugon M, Val-Casals M, Martin-Herreros B, et al
    A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
    Leukemia. 2025;39:2432-2441.
    >> Share

  76. MOINARD S, Lebecque B, Lachaise T, Johnson-Ansah H, et al
    Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
    Leukemia. 2025;39:2375-2383.
    >> Share

  77. TIRTAKUSUMA R, Ghonim MA, Schattgen S, Muller B, et al
    Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.
    Leukemia. 2025;39:2419-2431.
    >> Share

  78. ZHANG X, Li M, Chen Y, Liu J, et al
    Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression.
    Leukemia. 2025;39:2355-2363.
    >> Share

    September 2025
  79. VISENTIN A, Gaffo E, Furstenau M, Rogers KA, et al
    Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
    Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02755.
    >> Share

  80. MAZZEO P, Penir SM, Shumilov E, Wolf S, et al
    Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.
    Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02756.
    >> Share

  81. CUSAN M, Larkin K, Nicolet D, Jurinovic V, et al
    Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).
    Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02644.
    >> Share

  82. POLLYEA D, Kerre T, Deeren D, Beguin Y, et al
    Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.
    Leukemia. 2025 Sep 15. doi: 10.1038/s41375-025-02767.
    >> Share

  83. MIRANDA-GALVIS M, Tjioe KC, Sharara M, Maloney M, et al
    Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.
    Leukemia. 2025 Sep 11. doi: 10.1038/s41375-025-02763.
    >> Share

  84. KANARI M, Jimenez Garcia I, Steffen FD, Krattiger LA, et al
    A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.
    Leukemia. 2025 Sep 10. doi: 10.1038/s41375-025-02739.
    >> Share

  85. GONG X, Liu W, Liu Y, Fang Q, et al
    Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
    Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02696.
    >> Share

  86. VENDITTI A, Hou JZ, Fenaux P, Jonas BA, et al
    Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
    Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02730.
    >> Share

  87. MOCKING TR, Haaksma LH, Reuvekamp T, Kelder A, et al
    Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
    Leukemia. 2025 Sep 3. doi: 10.1038/s41375-025-02747.
    >> Share

  88. XU G, Wang F, Chen M, Gao W, et al
    Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.
    Leukemia. 2025 Sep 2. doi: 10.1038/s41375-025-02749.
    >> Share

  89. RONNACKER J, Muller PJ, Mikesch JH, Zukunft S, et al
    Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
    Leukemia. 2025;39:2174-2180.
    >> Share

  90. BERTOLI R, Cao D, Tuckey O, Gammell S, et al
    5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.
    Leukemia. 2025;39:2112-2124.
    >> Share

  91. VICK EJ, Hassan A, Choi K, Bennett J, et al
    Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization.
    Leukemia. 2025;39:2163-2173.
    >> Share

  92. CALDERON AS, Ghazanfari R, Masoumi Z, Kharazi S, et al
    Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state.
    Leukemia. 2025;39:2099-2111.
    >> Share

  93. NADEU F, Shuai S, Clot G, Hilton LK, et al
    Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
    Leukemia. 2025;39:2076-2086.
    >> Share

  94. ALFONSO-PIEROLA A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, et al
    Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.
    Leukemia. 2025 Sep 1. doi: 10.1038/s41375-025-02744.
    >> Share

    August 2025
  95. CURIK N, Laznicka A, Krizkova J, Suchankova P, et al
    Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.
    Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02732.
    >> Share

  96. HLEIHEL R, Skayneh H, Wu HC, Hamie M, et al
    Retinoic acid disrupts an NPM1c/ROS/SENP3/ARF oncogenic axis in acute myeloid leukemia.
    Leukemia. 2025 Aug 26. doi: 10.1038/s41375-025-02731.
    >> Share

  97. TELZEROW E, Gorlich D, Sauerland C, Rothenberg-Thurley M, et al
    Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.
    Leukemia. 2025 Aug 22. doi: 10.1038/s41375-025-02735.
    >> Share

  98. ZHENG J, Jin L, Chen Y, Duan Y, et al
    Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.
    Leukemia. 2025 Aug 21. doi: 10.1038/s41375-025-02743.
    >> Share

  99. FERRAO BLANCO MN, Kazybay B, Belderbos M, Heidenreich O, et al
    Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.
    Leukemia. 2025 Aug 15. doi: 10.1038/s41375-025-02734.
    >> Share

  100. AMARAL P, Christie R, Gresham DOF, Lucas EJM, et al
    Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Aug 14. doi: 10.1038/s41375-025-02723.
    >> Share

  101. WU K, Liu H, Hu W, Liu Y, et al
    Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.
    Leukemia. 2025 Aug 11. doi: 10.1038/s41375-025-02741.
    >> Share

  102. SUZUKI K, Kusayanagi S, Kuze Y, Hata M, et al
    Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-beta axis in adult T-cell leukemia/lymphoma.
    Leukemia. 2025 Aug 4. doi: 10.1038/s41375-025-02725.
    >> Share

  103. EHRMANN AS, Quijada-Alamo M, Close V, Guo M, et al
    NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.
    Leukemia. 2025;39:1892-1904.
    >> Share

  104. YAN J, Shi C, Yang G, Tian Z, et al
    T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.
    Leukemia. 2025;39:1948-1959.
    >> Share

  105. BERG V, Lollies A, Schneider M, Johansson P, et al
    Common origin and somatic mutation patterns of composite lymphomas and leukemias.
    Leukemia. 2025;39:1960-1971.
    >> Share

  106. ZOU J, Kinosada H, Takayanagi SI, Ishii T, et al
    KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.
    Leukemia. 2025;39:1848-1856.
    >> Share

    July 2025
  107. CALABRETTO G, Binatti A, Teramo A, Buratin A, et al
    Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations.
    Leukemia. 2025 Jul 28. doi: 10.1038/s41375-025-02708.
    >> Share

  108. LIEBER MR, Hsieh CL
    On the mechanism of NPM1 mutations in acute myeloid leukemia.
    Leukemia. 2025 Jul 28. doi: 10.1038/s41375-025-02722.
    >> Share

  109. YANG C, Kang YY, Zhu CY, Ma Y, et al
    Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Jul 22. doi: 10.1038/s41375-025-02709.
    >> Share

  110. BOND DR, Burnard SM, Uddipto K, Hunt KV, et al
    Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal.
    Leukemia. 2025 Jul 17. doi: 10.1038/s41375-025-02693.
    >> Share

  111. KELEKCI S, Kelly K, Goyal A, Wehrwein N, et al
    DNA demethylation-mediated downregulation of MNX1 in acute myeloid leukemia.
    Leukemia. 2025 Jul 14. doi: 10.1038/s41375-025-02680.
    >> Share

  112. ZHAO Y, Cao W, Shi J, Cao Y, et al
    Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms.
    Leukemia. 2025 Jul 14. doi: 10.1038/s41375-025-02672.
    >> Share

  113. APPERLEY JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, et al
    2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
    Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02664.
    >> Share

  114. RETTINGER E, Heckl D, Gibson B, Sauer M, et al
    The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.
    Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02685.
    >> Share

  115. SKULI SJ, Bakayoko A, Kruidenier M, Manning B, et al
    Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
    Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02668.
    >> Share

  116. OKSA L, Moisio S, Maqbool K, Kramer R, et al
    Genomic determinants of therapy response in ETV6::RUNX1 leukemia.
    Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02683.
    >> Share

  117. RONNACKER J, Ruhnke L, Rollig C, Middeke JM, et al
    Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment.
    Leukemia. 2025 Jul 3. doi: 10.1038/s41375-025-02675.
    >> Share

    June 2025
  118. GONG X, Liu W, Liu Y, Fang Q, et al
    Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
    Leukemia. 2025 Jun 30. doi: 10.1038/s41375-025-02674.
    >> Share

  119. WANG M, Zhu R, Small D, Lin L, et al
    SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells.
    Leukemia. 2025 Jun 30. doi: 10.1038/s41375-025-02673.
    >> Share

  120. GRASSI F, Singh M, Moussaud S, Rodriguez GV, et al
    DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT.
    Leukemia. 2025 Jun 26. doi: 10.1038/s41375-025-02661.
    >> Share

  121. WELCH BM, Parikh SA, Kay NE, Medina KL, et al
    Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients.
    Leukemia. 2025 Jun 26. doi: 10.1038/s41375-025-02579.
    >> Share

  122. PEPE S, Vitale C, Giannarelli D, Visentin A, et al
    Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
    Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02666.
    >> Share

  123. YU H, Hong J, Shin DY, Lee CH, et al
    The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.
    Leukemia. 2025 Jun 25. doi: 10.1038/s41375-025-02657.
    >> Share

  124. DING Y, He B, Bogush D, Schramm J, et al
    Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02651.
    >> Share

  125. CSIZMAR CM, Natu A, Gurney M, Fathima S, et al
    Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
    Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02648.
    >> Share

  126. BLOMBERY P, Chatzikonstantinou T, Gerousi M, Rosenquist R, et al
    Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
    Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662.
    >> Share

  127. LEBON D, Da Rocha A, Cassinat B, Heiblig M, et al
    Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia.
    Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02663.
    >> Share

  128. MASHIMA K, Kuang Y, Fernandes SM, Xu S, et al
    Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia.
    Leukemia. 2025 Jun 23. doi: 10.1038/s41375-025-02611.
    >> Share

  129. VIT F, Bittolo T, Zucchetto A, Papotti R, et al
    Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
    Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02650.
    >> Share

  130. IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al
    Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
    Leukemia. 2025;39:1362-1367.
    >> Share

  131. BUCKLEY M, Yeung DT, White DL, Eadie LN, et al
    T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
    Leukemia. 2025;39:1294-1310.
    >> Share

  132. VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al
    CLL cell-derived exosomes alter the immune and hematopoietic systems.
    Leukemia. 2025;39:1380-1394.
    >> Share

    May 2025
  133. ZHANG Y, Feng Z, Du J, Liu H, et al
    High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
    Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655.
    >> Share

  134. BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
    Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.
    Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653.
    >> Share

  135. DEMBITZ V, James SC, Gallipoli P
    Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.
    Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
    >> Share

  136. AUER F, Morcos MNF, Sipola M, Akhtar I, et al
    Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
    Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
    >> Share

  137. KUHN MWM, Pemmaraju N, Heidel FH
    The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
    Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639.
    >> Share

  138. NGUYEN NTK, Yao H, Hosokawa K, Esaki Y, et al
    Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-beta-activated Alcam(+) bone lining cells, creating a self-sustaining environment.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02640.
    >> Share

  139. WANG'ONDU RW, Ashcraft E, Chang TC, Roberts KG, et al
    Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633.
    >> Share

  140. BATALLER A, Goulart HE, Issa GC, DiNardo CD, et al
    Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
    Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634.
    >> Share

  141. IZUMI S, Ohtani K, Matsumoto M, Shibata S, et al
    Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia.
    Leukemia. 2025 May 8. doi: 10.1038/s41375-025-02638.
    >> Share

  142. NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
    Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 May 5. doi: 10.1038/s41375-025-02637.
    >> Share

  143. LAUSEKER M, Hoffmann VS, Pfirrmann M
    Prognostic scoring systems in chronic myeloid leukaemia.
    Leukemia. 2025;39:1046-1052.
    >> Share

  144. TAKAMORI H, Huang YJ, Fukushima H, Yokoyama K, et al
    Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation.
    Leukemia. 2025;39:1218-1227.
    >> Share

    April 2025
  145. HASAN MK, Widhopf Ii GF, Ghia EM, Kipps TJ, et al
    Wnt5a induces ROR1 dependent NF-kappaB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616.
    >> Share

  146. MECKLENBRAUCK R, Borchert N, Gabdoulline R, Poll P, et al
    Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622.
    >> Share

  147. KRIZKOVA J, Polivkova V, Laznicka A, Curik N, et al
    Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609.
    >> Share

  148. GHANI F, Zubair AC
    Possible impacts of cosmic radiation on leukemia development during human deep space exploration.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02624.
    >> Share

  149. THORVALDSDOTTIR B, Mansouri L, Sutton LA, Nadeu F, et al
    ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02615.
    >> Share

  150. ZHOU T, Short NJ, Jain N, Patel KP, et al
    Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588.
    >> Share

  151. GAZEAU N, Beauvais D, Tilmont R, Srour M, et al
    Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02605.
    >> Share

  152. WU JF, Feliciano EJG, Singh A, Tremblay D, et al
    National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients.
    Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02598.
    >> Share

  153. SHIMA Y, Yamagata K, Kuroki Y, Sasaki K, et al
    Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.
    Leukemia. 2025 Apr 22. doi: 10.1038/s41375-025-02607.
    >> Share

  154. ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
    Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
    Leukemia. 2025 Apr 16. doi: 10.1038/s41375-025-02608.
    >> Share

  155. XU Y, Mou J, Wang Y, Zhou W, et al
    Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02618.
    >> Share

  156. NIEDERMAYER A, Stursberg J, Bergmann AK, Zimmermann M, et al
    Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02591.
    >> Share

  157. DECHOW A, Timonen S, Ianevski A, Jiang Q, et al
    Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577.
    >> Share

  158. HSU CJ, Schraw JM, Desrosiers TA, Janitz AE, et al
    All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome.
    Leukemia. 2025 Apr 11. doi: 10.1038/s41375-025-02602.
    >> Share

  159. XING C, Zhang H, Zheng M, Lu Q, et al
    Fabp4 is essential for the maintenance of leukemia stem cells while sparing hematopoietic stem cells.
    Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02568.
    >> Share

  160. CORTES JE, Lang F, Rea D, Hochhaus A, et al
    Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592.
    >> Share

  161. KAYA F, Bewicke-Copley F, Miettinen JJ, Casado P, et al
    DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02593.
    >> Share

  162. HOCHHAUS A, Kim DW, Cortes JE, Sasaki K, et al
    Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578.
    >> Share

  163. PAGANO L, Maschmeyer G, Lamoth F, Blennow O, et al
    Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586.
    >> Share

  164. REINHARDT C, Ochsenbein AF
    Immune checkpoints regulate acute myeloid leukemia stem cells.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566.
    >> Share

  165. LI R, Wu X, Xue K, Wu S, et al
    CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02589.
    >> Share

  166. BUSSOT L, Poulain S, Nudel Ortmans M, Davi F, et al
    Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
    Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02555.
    >> Share

  167. HUANG J, Xie J, Wang Y, Sheng M, et al
    STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells.
    Leukemia. 2025;39:929-941.
    >> Share

  168. SHI C, Tian Z, Yan J, Zhang M, et al
    Immunotherapy targeting a leader sequence cathepsin G-derived peptide.
    Leukemia. 2025;39:888-898.
    >> Share

    March 2025
  169. AYYADEVARA VSSA, Wertheim G, Gaur S, Chukinas JA, et al
    DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02575.
    >> Share

  170. CHARLES CANO F, Kloos A, Hebalkar RY, Plenge T, et al
    XPO1-dependency of DEK::NUP214 leukemia.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02570.
    >> Share

  171. JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al
    Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
    Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573.
    >> Share

  172. STOLTZE U, Junk SV, Byrjalsen A, Cave H, et al
    Overt and covert genetic causes of pediatric acute lymphoblastic leukemia.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02535.
    >> Share

  173. GEYER J, Opoku KB, Lin J, Ramkissoon L, et al
    Real-time genomic characterization of pediatric acute leukemia using adaptive sampling.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02565.
    >> Share

  174. COLE FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, et al
    Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
    Leukemia. 2025 Mar 21. doi: 10.1038/s41375-025-02571.
    >> Share

  175. ROMPIETTI C, Adamo FM, Sorcini D, De Falco F, et al
    Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.
    Leukemia. 2025 Mar 20. doi: 10.1038/s41375-025-02557.
    >> Share

  176. SHAH BD, Cassaday RD, Park JH, Houot R, et al
    Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
    Leukemia. 2025 Mar 19. doi: 10.1038/s41375-025-02532.
    >> Share

  177. SPERB N, Maksakova IA, Escano L, Abraham L, et al
    The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.
    Leukemia. 2025 Mar 17. doi: 10.1038/s41375-025-02558.
    >> Share

  178. WANG H, Suo S, Li D, Li J, et al
    Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.
    Leukemia. 2025 Mar 12. doi: 10.1038/s41375-025-02556.
    >> Share

  179. KLEPZIG H, Herling M, Pflug N, Braun T, et al
    Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
    Leukemia. 2025 Mar 7. doi: 10.1038/s41375-025-02553.
    >> Share

  180. MILLOT F, Ampatzidou M, Moulik NR, Tewari S, et al
    Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02543.
    >> Share

  181. LIPTON JH, Rea D
    Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02548.
    >> Share

  182. BRUNMEIR R, Ying L, Yan J, Hee YT, et al
    EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.
    Leukemia. 2025;39:650-662.
    >> Share

    February 2025
  183. REUVEKAMP T, Ngai LL, den Hartog D, Carbaat-Ham J, et al
    CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
    Leukemia. 2025 Feb 27. doi: 10.1038/s41375-025-02539.
    >> Share

  184. DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
    Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02531.
    >> Share

  185. GIUDICE V, Selleri C
    How fast does leukemia progress?
    Leukemia. 2025 Feb 24. doi: 10.1038/s41375-025-02536.
    >> Share

  186. MINAMI M, Sakoda T, Kawano G, Kochi Y, et al
    Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARalpha.
    Leukemia. 2025 Feb 20. doi: 10.1038/s41375-025-02530.
    >> Share

  187. HORMANN FM, Rudd SG
    Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
    Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02529.
    >> Share

  188. ABEDIN SM, Guru Murthy GS, Hamadani M, Michaelis LC, et al
    Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 15. doi: 10.1038/s41375-025-02528.
    >> Share

  189. OKABE S, Arai Y, Gotoh A
    Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
    Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521.
    >> Share

  190. SU Y, Han Z, Ji Y, Liu A, et al
    Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.
    Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514.
    >> Share

  191. FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al
    Functions of the native NPM1 protein and its leukemic mutant.
    Leukemia. 2025;39:276-290.
    >> Share

  192. YANG S, Zhang X, Gale RP, Huang X, et al
    Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
    Leukemia. 2025;39:391-399.
    >> Share

  193. CALVO J, Naguibneva I, Kypraios A, Gilain F, et al
    High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
    Leukemia. 2025;39:323-336.
    >> Share

  194. ORTI G, Peczynski C, Boreland W, O'Reilly M, et al
    Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
    Leukemia. 2025;39:431-437.
    >> Share

    January 2025
  195. ABLE M, Kasper MA, Vick B, Schwach J, et al
    Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.
    Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02510.
    >> Share

  196. LIU J, Kharazmi E, Liang Q, Chen Y, et al
    Maternal weight during pregnancy and risk of childhood acute lymphoblastic leukemia in offspring.
    Leukemia. 2025 Jan 26. doi: 10.1038/s41375-025-02517.
    >> Share

  197. TREMBLAY CS, Saw J, Yan F, Boyle JA, et al
    Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 23. doi: 10.1038/s41375-024-02491.
    >> Share

  198. LAUWEREINS L, Van Thillo Q, Demeyer S, Mentens N, et al
    TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 21. doi: 10.1038/s41375-025-02513.
    >> Share

  199. ADDINSELL HM, Cant R, Hull NJ, Wang YH, et al
    Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.
    Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02511.
    >> Share

  200. ANABTAWI N, Nicolet D, Alotaibi N, Buelow DR, et al
    Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
    Leukemia. 2025 Jan 13. doi: 10.1038/s41375-024-02498.
    >> Share

  201. SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al
    A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
    Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501.
    >> Share

  202. SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al
    NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation.
    Leukemia. 2025;39:75-86.
    >> Share

  203. STRULLU M, Caye-Eude A, Robert E, Renard JM, et al
    CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
    Leukemia. 2025;39:64-74.
    >> Share

  204. JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al
    Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
    Leukemia. 2025;39:166-177.
    >> Share

  205. LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al
    The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
    Leukemia. 2025;39:87-97.
    >> Share

    December 2024
  206. SHI Z, Li J, Ding J, Zhang Y, et al
    ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
    Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
    >> Share

  207. NABKI J, Al Deeban B, Sium AM, Cosentino C, et al
    Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
    Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
    >> Share

  208. BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al
    Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
    Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
    >> Share

  209. ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al
    Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
    >> Share

  210. GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al
    Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
    >> Share

  211. SHIMA H, Tono C, Tanizawa A, Ito M, et al
    Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
    >> Share

  212. ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al
    Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
    Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
    >> Share

  213. MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al
    Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
    >> Share

  214. HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
    Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
    >> Share

  215. ARZA-APALATEGI S, Heuts BMH, Bergevoet SM, Meering R, et al
    HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.
    Leukemia. 2024 Dec 4. doi: 10.1038/s41375-024-02485.
    >> Share

  216. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
    Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487.
    >> Share

  217. WALTER W, Nadarajah N, Hutter S, Muller H, et al
    Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
    Leukemia. 2024;38:2644-2652.
    >> Share

  218. HALILOVIC M, Abdelsalam M, Zabkiewicz J, Lazenby M, et al
    Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
    Leukemia. 2024;38:2561-2572.
    >> Share

    November 2024
  219. LOU J, Zhang Y, Tao J, Jin W, et al
    Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA.
    Leukemia. 2024 Nov 28. doi: 10.1038/s41375-024-02481.
    >> Share

  220. HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al
    The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471.
    >> Share

  221. KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al
    Clonal hematopoiesis in large granular lymphocytic leukemia.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460.
    >> Share

  222. DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al
    Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
    Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452.
    >> Share

  223. KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al
    The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
    Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454.
    >> Share

  224. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
    Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
    Leukemia. 2024 Nov 13. doi: 10.1038/s41375-024-02472.
    >> Share

  225. TREMBLAY D, Csizmar C, DiNardo CD, Ball S, et al
    Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
    Leukemia. 2024 Nov 12. doi: 10.1038/s41375-024-02466.
    >> Share

  226. BOUEYA IL, Sandhow L, Albuquerque JRP, Znaidi R, et al
    Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.
    Leukemia. 2024 Nov 11. doi: 10.1038/s41375-024-02453.
    >> Share

  227. LI X, Zheng M, Ma S, Nie F, et al
    YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02451.
    >> Share

  228. EL CHAER F, Perissinotti AJ, Loghavi S, Zeidan AM, et al
    Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02458.
    >> Share

  229. SHAO X, Yokomori R, Ong JZL, Shen H, et al
    Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Nov 2. doi: 10.1038/s41375-024-02455.
    >> Share

  230. INNES AJ, Hayden C, Orovboni V, Claudiani S, et al
    Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
    Leukemia. 2024;38:2443-2455.
    >> Share

    October 2024
  231. SHIMONI A, Peczynski C, Labopin M, Kulagin A, et al
    Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
    Leukemia. 2024 Oct 31. doi: 10.1038/s41375-024-02445.
    >> Share

  232. SAFA-TAHAR-HENNI S, Paez Martinez K, Gress V, Esparza N, et al
    Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
    Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400.
    >> Share

  233. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
    Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
    Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448.
    >> Share

  234. NARDI F, Del Prete R, Drago R, Di Rita A, et al
    Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia.
    Leukemia. 2024 Oct 23. doi: 10.1038/s41375-024-02442.
    >> Share

  235. YU M, Nah GSS, Krishnan V, Sulaimi FNB, et al
    The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.
    Leukemia. 2024 Oct 22. doi: 10.1038/s41375-024-02418.
    >> Share

  236. YANG C, Hu Y, Gao L, Li Z, et al
    Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
    Leukemia. 2024 Oct 15. doi: 10.1038/s41375-024-02437.
    >> Share

  237. TETTERO JM, Cloos J, Bullinger L
    Acute myeloid leukemia: does sex matter?
    Leukemia. 2024 Oct 14. doi: 10.1038/s41375-024-02435.
    >> Share

  238. YAMAMOTO Y, Iba S, Inaguma Y, Okamoto A, et al
    ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
    Leukemia. 2024 Oct 8. doi: 10.1038/s41375-024-02434.
    >> Share

  239. SUNAMI Y, Yoshino S, Yamazaki Y, Iwamoto T, et al
    Rapid increase of C/EBPalpha p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML.
    Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02430.
    >> Share

  240. ZHANG N, Wen D, Wang T, Deng J, et al
    Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes.
    Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02433.
    >> Share

  241. GODA C, Kulkarni R, Bustos Y, Li W, et al
    Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
    Leukemia. 2024 Oct 2. doi: 10.1038/s41375-024-02415.
    >> Share

  242. KAZERANI M, Marcinek A, Philipp N, Brauchle B, et al
    Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
    Leukemia. 2024;38:2270-2275.
    >> Share

  243. LEE YJ, Lee SY, Kim S, Kim SH, et al
    REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.
    Leukemia. 2024;38:2150-2161.
    >> Share

  244. GALE RP, Jiang Q, Apperley JF, Hochhaus A, et al
    Is there really an accelerated phase of chronic myeloid leukaemia?
    Leukemia. 2024;38:2085-2086.
    >> Share

    September 2024
  245. PATEL SA
    Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
    Leukemia. 2024 Sep 30. doi: 10.1038/s41375-024-02417.
    >> Share

  246. SAKAMOTO KM
    Can PROTACs cure Leukemia?
    Leukemia. 2024 Sep 26. doi: 10.1038/s41375-024-02427.
    >> Share

  247. RAVANDI F, Senapati J, Jain N, Short NJ, et al
    Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414.
    >> Share

  248. HUELSE JM, Bhasin SS, Jacobsen KM, Yim J, et al
    MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02408.
    >> Share

  249. VOLTA L, Myburgh R, Pellegrino C, Koch C, et al
    Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
    Leukemia. 2024 Sep 18. doi: 10.1038/s41375-024-02409.
    >> Share

  250. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
    Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
    Leukemia. 2024 Sep 17. doi: 10.1038/s41375-024-02412.
    >> Share

  251. ZHANG W, Yamamoto K, Chang YH, Yabushita T, et al
    HDAC7 is a potential therapeutic target in acute erythroid leukemia.
    Leukemia. 2024 Sep 15. doi: 10.1038/s41375-024-02394.
    >> Share

  252. LIU B, Zhang X, Zhou Y, Liu H, et al
    USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression.
    Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02338.
    >> Share

  253. RABIAN F, Chevret S, Gruson B, Thepot S, et al
    Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myelodysplasies (GFM) study.
    Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02402.
    >> Share

  254. KORBECKI J, Bosiacki M, Kupnicka P, Barczak K, et al
    CXCR4 as a therapeutic target in acute myeloid leukemia.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02326.
    >> Share

  255. HAGERSTRAND D, Oder B, Cortese D, Qu Y, et al
    The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02379.
    >> Share

  256. RHEINGOLD SR, Bhojwani D, Ji L, Xu X, et al
    Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02395.
    >> Share

  257. STUTTERHEIM J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, et al
    Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
    Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386.
    >> Share

  258. LIU T, Xu K, Pardeshi A, Myint SS, et al
    Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia.
    Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02407.
    >> Share

  259. BOUCHER A, Murray J, Rao S
    Cohesin mutations in acute myeloid leukemia.
    Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02406.
    >> Share

  260. WANG J, Jiang B, Li J, Liu L, et al
    Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
    Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382.
    >> Share

  261. VAN DER HAM CG, Suurenbroek LC, Kleisman MM, Antic Z, et al
    Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.
    Leukemia. 2024 Sep 4. doi: 10.1038/s41375-024-02403.
    >> Share

  262. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02385.
    >> Share

  263. TOMA MM, Skorski T
    Star wars against leukemia: attacking the clones.
    Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369.
    >> Share

  264. CRUZ-RODRIGUEZ N, Tang H, Bateman B, Tang W, et al
    BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph(+) leukemias?
    Leukemia. 2024;38:1885-1893.
    >> Share

  265. LEYTE-VIDAL A, DeFilippis R, Outhwaite IR, Kwan I, et al
    Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
    Leukemia. 2024;38:2046-2050.
    >> Share

  266. PIEMONTESE S, Labopin M, Choi G, Broers AEC, et al
    Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
    Leukemia. 2024;38:2016-2022.
    >> Share

  267. JANN JC, Hergott CB, Winkler M, Liu Y, et al
    Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
    Leukemia. 2024;38:1992-2002.
    >> Share

  268. WANG J, Zhang Y, Li L, Wang L, et al
    Nudt15-mediated inflammatory signaling contributes to divergent outcomes in leukemogenesis and hematopoiesis.
    Leukemia. 2024;38:1958-1970.
    >> Share

  269. KEWAN T, Bahaj WS, Gurnari C, Ogbue OD, et al
    Clinical and molecular characteristics of extramedullary acute myeloid leukemias.
    Leukemia. 2024;38:2032-2036.
    >> Share

  270. AL AMRI R, Baloda V, Monaghan SA, Rosado FG, et al
    Validation of independent prognostic significance of blast count in a large cohort of MDS patients.
    Leukemia. 2024;38:2064-2067.
    >> Share

  271. SPERK A, Gabriel A, Koch D, Augsburger A, et al
    FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
    Leukemia. 2024;38:2027-2031.
    >> Share

  272. JALNAPURKAR SS, Pawar AS, George SS, Antony C, et al
    PHF6 suppresses self-renewal of leukemic stem cells in AML.
    Leukemia. 2024;38:1938-1948.
    >> Share

  273. MOORMAN AV, Enshaei A, Murdy D, Joy M, et al
    Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
    Leukemia. 2024;38:2023-2026.
    >> Share

  274. HERNANDEZ-SANCHEZ A, Gonzalez T, Sobas M, Strang E, et al
    Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
    Leukemia. 2024;38:1929-1937.
    >> Share

  275. LESKE IB, Hantschel O
    The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
    Leukemia. 2024;38:2041-2045.
    >> Share

    August 2024
  276. DERIGS P, Schubert ML, Dreger P, Schmitt A, et al
    Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
    Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392.
    >> Share

  277. PASTORCZAK A, Urbanska Z, Styka B, Miarka-Walczyk K, et al
    Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02370.
    >> Share

  278. DEMBITZ V, Lawson H, Burt R, Natani S, et al
    Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.
    Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02390.
    >> Share

  279. KOEDIJK JB, van der Werf I, Penter L, Vermeulen MA, et al
    A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia.
    Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02381.
    >> Share

  280. CUGLIEVAN B, Kantarjian H, Rubnitz JE, Cooper TM, et al
    Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
    Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02368.
    >> Share

  281. SUN Y, Wu Y, Pang G, Huang J, et al
    STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.
    Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02383.
    >> Share

  282. RODRIGUEZ-ARBOLI E, Othus M, Freeman SD, Buccisano F, et al
    Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
    Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02378.
    >> Share

  283. BOUTZEN H, Murison A, Oriecuia A, Bansal S, et al
    Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties.
    Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02358.
    >> Share

  284. GAMBACORTI-PASSERINI C, Brummendorf TH, Abruzzese E, Kelly KR, et al
    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
    Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372.
    >> Share

  285. TISSINO E, Gaglio A, Nicolo A, Pozzo F, et al
    The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
    Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376.
    >> Share

  286. ATAR D, Ruoff L, Mast AS, Krost S, et al
    Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
    Leukemia. 2024 Aug 3. doi: 10.1038/s41375-024-02351.
    >> Share

  287. CHATAIN N, Baumeister J, Szymanski de Toledo MA, Wong DWL, et al
    Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
    Leukemia. 2024;38:1825-1830.
    >> Share

  288. HOFERKOVA E, Seda V, Kadakova S, Verner J, et al
    Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.
    Leukemia. 2024;38:1699-1711.
    >> Share

  289. BOUSQUETS-MUNOZ P, Molina O, Varela I, Alvarez-Eguiluz A, et al
    Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML.
    Leukemia. 2024;38:1808-1812.
    >> Share

  290. FONTANA D, Malighetti F, Villa M, Zambon A, et al
    Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
    Leukemia. 2024;38:1843-1847.
    >> Share

  291. FARHAT M, Croft W, Parry HM, Verma K, et al
    PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL.
    Leukemia. 2024;38:1813-1817.
    >> Share

  292. GALE RP, Phillips GL, Lazarus HM
    A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.
    Leukemia. 2024;38:1663-1666.
    >> Share

    July 2024
  293. WONG RL, Choi MY, Wang HY, Kipps TJ, et al
    Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
    Leukemia. 2024 Jul 24. doi: 10.1038/s41375-024-02317.
    >> Share

  294. KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al
    Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339.
    >> Share

  295. ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al
    Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
    Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335.
    >> Share

  296. TERASAKI T, Semba Y, Sasaki K, Imanaga H, et al
    The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
    Leukemia. 2024 Jul 11. doi: 10.1038/s41375-024-02343.
    >> Share

  297. EFFICACE F, Mahon FX, Richter J, Piciocchi A, et al
    Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
    Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341.
    >> Share

  298. OGBUE O, Kewan T, Bravo-Perez C, Unlu S, et al
    Hemolytic versus malproductive anemia in large granular lymphocytic leukemia.
    Leukemia. 2024 Jul 9. doi: 10.1038/s41375-024-02323.
    >> Share

  299. KIM H, Tan TK, Lee DZY, Huang XZ, et al
    Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jul 5. doi: 10.1038/s41375-024-02331.
    >> Share

  300. ERNST P, Rinke J, Franke GN, Dicker F, et al
    Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
    Leukemia. 2024 Jul 4. doi: 10.1038/s41375-024-02327.
    >> Share

  301. DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
    Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
    Leukemia. 2024 Jul 3. doi: 10.1038/s41375-024-02291.
    >> Share

  302. YAMAMOTO Y, Watanabe T, Ureshino H, Kurahashi Y, et al
    DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.
    Leukemia. 2024;38:1613-1616.
    >> Share

  303. SHAO Y, Kay NE, Gale RP, Liang Y, et al
    Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
    Leukemia. 2024;38:1469-1473.
    >> Share

  304. SCOTT S, Devonshire A, Dillon R, Thiede C, et al
    Recommendations from the AML molecular MRD expert advisory board.
    Leukemia. 2024;38:1638-1641.
    >> Share

  305. MASLAH N, Rety S, Bonnamy M, Aguinaga L, et al
    Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
    Leukemia. 2024;38:1630-1633.
    >> Share

  306. GROSS G, Alkadieri S, Meir A, Itzhaki O, et al
    Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose.
    Leukemia. 2024;38:1534-1540.
    >> Share

  307. SHIMONY S, Garcia JS, Keating J, Chen EC, et al
    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
    Leukemia. 2024;38:1494-1500.
    >> Share

  308. KOVECSES O, Mercier FE, McKeague M
    Nucleic acid therapeutics as differentiation agents for myeloid leukemias.
    Leukemia. 2024;38:1441-1454.
    >> Share

    June 2024
  309. YUN H, Zoller J, Zhou F, Rohde C, et al
    The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.
    Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322.
    >> Share

  310. GALE RP, Hochhaus A
    Correction: To Mars and beyond. Space exploration and space medicine in Leukemia.
    Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02324.
    >> Share

  311. POZZO F, Forestieri G, Vit F, Ianna G, et al
    Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
    Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02301.
    >> Share

  312. YANAGIYA R, Miyatake Y, Watanabe N, Shimizu T, et al
    Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.
    Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02296.
    >> Share

  313. PHILIPPE C, Jaud M, Feral K, Gay A, et al
    Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy.
    Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02321.
    >> Share

  314. ABOU DALLE I, Moukalled N, El Cheikh J, Mohty M, et al
    Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.
    Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02319.
    >> Share

  315. MCCARTHY N, Gui G, Dumezy F, Roumier C, et al
    Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
    Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02300.
    >> Share

  316. MIAO H, Chen D, Ropa J, Purohit T, et al
    Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
    Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02312.
    >> Share

  317. SALA-TORRA O, Beppu L, Wu Q, Welch E, et al
    Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients.
    Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02285.
    >> Share

  318. GREVER M, Andritsos L, Anghelina M, Arons E, et al
    Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
    Leukemia. 2024 Jun 8. doi: 10.1038/s41375-024-02280.
    >> Share

  319. OSTERGAARD A, Fiocco M, de Groot-Kruseman H, Moorman AV, et al
    ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
    Leukemia. 2024 Jun 6. doi: 10.1038/s41375-024-02287.
    >> Share

  320. ZHANG MY, Othus M, McMillen K, Erba HP, et al
    Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
    Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02288.
    >> Share

  321. VAN DER VELDEN VHJ, Dombrink I, Alten J, Cazzaniga G, et al
    Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
    Leukemia. 2024;38:1315-1322.
    >> Share

  322. SAYITOGLU EC, Luca BA, Boss AP, Thomas BC, et al
    AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.
    Leukemia. 2024;38:1246-1255.
    >> Share

  323. YANG M, Ma Z, Wang C, Agca MC, et al
    Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD.
    Leukemia. 2024;38:1437-1439.
    >> Share

  324. LU W, Lyu H, Xiao X, Bai X, et al
    Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2024;38:1419-1422.
    >> Share

  325. VAN SPRONSEN MF, Van Gassen S, Duetz C, Westers TM, et al
    Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
    Leukemia. 2024;38:1365-1377.
    >> Share

  326. PERZOLLI A, Koedijk JB, Zwaan CM, Heidenreich O, et al
    Targeting the innate immune system in pediatric and adult AML.
    Leukemia. 2024;38:1191-1201.
    >> Share

    May 2024
  327. ZHU R, Shirley CM, Chu SH, Li L, et al
    Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
    Leukemia. 2024 May 29. doi: 10.1038/s41375-024-02292.
    >> Share

  328. GALE RP, Hochhaus A
    To Mars and beyond. Space exploration and space medicine in Leukemia.
    Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286.
    >> Share

  329. RUJKIJYANONT P, Inaba H
    Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
    Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277.
    >> Share

  330. CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
    Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
    >> Share

  331. MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
    >> Share

  332. NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
    Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
    Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
    >> Share

  333. KARAMI A, Skorski T
    DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.
    >> Share

  334. AWADA H, Durmaz A, Kewan T, Ullah F, et al
    Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.
    >> Share

  335. MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
    TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
    >> Share

  336. O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al
    The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
    Leukemia. 2024;38:951-962.
    >> Share

  337. SRINIVASAN S, Keerthivasagam S
    Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights.
    Leukemia. 2024;38:1187-1188.
    >> Share

  338. SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al
    CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
    Leukemia. 2024;38:963-968.
    >> Share

  339. WONG JC, Weinfurtner KM, Westover T, Kim J, et al
    5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
    Leukemia. 2024;38:1182-1186.
    >> Share

  340. YI W, Zhang J, Huang Y, Zhan Q, et al
    Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells.
    Leukemia. 2024;38:1003-1018.
    >> Share

    April 2024
  341. GUO J, Buettner R, Du L, Li Z, et al
    8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia.
    Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
    >> Share

  342. IYODA S, Yoshida K, Shoji K, Ito N, et al
    KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
    >> Share

  343. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
    Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
    Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
    >> Share

  344. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
    Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
    >> Share

  345. MATSUI S, Ri C, Bolanos LC, Choi K, et al
    Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
    Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
    >> Share

  346. BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
    Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
    >> Share

  347. FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
    Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
    >> Share

  348. BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
    IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
    >> Share

  349. MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
    Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    Leukemia. 2024;38:699-711.
    >> Share

  350. LUBKE J, Christen D, Schwaab J, Kaiser A, et al
    Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
    Leukemia. 2024;38:810-821.
    >> Share

  351. SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
    Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Leukemia. 2024;38:762-768.
    >> Share

  352. SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
    Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
    Leukemia. 2024;38:918-922.
    >> Share

  353. SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
    Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
    Leukemia. 2024;38:751-761.
    >> Share

    March 2024
  354. JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
    A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
    Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
    >> Share

  355. BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
    Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
    Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
    >> Share

  356. DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
    Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
    >> Share

  357. KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
    Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.
    >> Share

  358. BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.
    >> Share

  359. FARROKHI A, Atre T, Rever J, Fidanza M, et al
    The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
    >> Share

  360. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
    NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
    Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
    >> Share

  361. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
    Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
    Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
    >> Share

  362. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
    Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
    Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
    >> Share

  363. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
    >> Share

  364. THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
    Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
    Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
    >> Share

  365. PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
    Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
    Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.
    >> Share

  366. MA J, Liu YC, Voss RK, Ma J, et al
    Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
    Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
    >> Share

  367. CHEN CC, Silberman RE, Ma D, Perry JA, et al
    Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
    Leukemia. 2024;38:521-529.
    >> Share

  368. SANZ-ORTEGA L, Andersson A, Carlsten M
    Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
    Leukemia. 2024;38:579-589.
    >> Share

  369. PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
    Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
    Leukemia. 2024;38:491-501.
    >> Share

  370. SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
    DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
    Leukemia. 2024;38:530-537.
    >> Share

  371. BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
    Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Leukemia. 2024;38:545-556.
    >> Share

    February 2024
  372. CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al
    Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
    >> Share

  373. YANG X, Liu J, Liu W, Wu H, et al
    circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
    >> Share

  374. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.
    >> Share

  375. MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al
    Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.
    >> Share

  376. JUNK SV, Forster A, Schmidt G, Zimmermann M, et al
    Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
    Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.
    >> Share

  377. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
    Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
    Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183.
    >> Share

  378. OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al
    Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172.
    >> Share

  379. AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al
    Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177.
    >> Share

  380. CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al
    Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163.
    >> Share

  381. LIN S, Schneider C, Su AH, Alexe G, et al
    The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178.
    >> Share

  382. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
    Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
    >> Share

  383. LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
    LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
    Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.
    >> Share

  384. FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
    State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
    Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
    >> Share

  385. KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
    Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
    Leukemia. 2024;38:386-388.
    >> Share

  386. ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
    Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
    Leukemia. 2024;38:455-459.
    >> Share

  387. GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
    Prognostic impact of CEBPA mutational subgroups in adult AML.
    Leukemia. 2024;38:281-290.
    >> Share

  388. HEHLMANN R, Lauseker M
    How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
    Leukemia. 2024;38:465-466.
    >> Share

  389. CHEN J, Gale RP
    Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
    Leukemia. 2024;38:463-464.
    >> Share

  390. LEE KH, Lee S, Park YH, Mun YC, et al
    Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
    Leukemia. 2024;38:451-454.
    >> Share

  391. MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
    Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
    Leukemia. 2024;38:258-265.
    >> Share

  392. CHEN Y, Wen J, Li Q, Peng D, et al
    RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
    Leukemia. 2024;38:266-280.
    >> Share

  393. SUI P, Ge G, Chen S, Bai J, et al
    SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
    Leukemia. 2024;38:408-411.
    >> Share

    January 2024
  394. DAM M, Centanni M, Friberg LE, Centanni D, et al
    Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
    >> Share

  395. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
    >> Share

  396. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
    >> Share

  397. TAN SH, Tan TK, Yokomori R, Liao M, et al
    Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.
    >> Share

  398. TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
    >> Share

  399. APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
    Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.
    >> Share

  400. KANG H, Hoang DH, Valerio M, Pathak K, et al
    OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
    Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146.
    >> Share

  401. TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al
    Clonal medicine targeting DNA damage response eradicates leukemia.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138.
    >> Share

  402. CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al
    Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136.
    >> Share

  403. HANEL G, Schonle A, Neumann AS, Nixdorf D, et al
    Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
    Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127.
    >> Share

  404. VALTIS YK, Flamand Y, Shimony S, Place AE, et al
    Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115.
    >> Share

  405. SUNG PJ, Selvam M, Riedel SS, Xie HM, et al
    FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131.
    >> Share

  406. POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al
    Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
    Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118.
    >> Share

  407. MORLEY AA
    Quantifying measurable residual disease correctly.
    Leukemia. 2024;38:221-222.
    >> Share

  408. TYAGI A, Jaggupilli A, Ly S, Yuan B, et al
    TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
    Leukemia. 2024;38:82-95.
    >> Share

  409. ZHOU YL, Zhao MY, Gale RP, Jiang H, et al
    Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
    Leukemia. 2024;38:223-225.
    >> Share

  410. CHEN J
    Response to comment on Have we been qualifying measurable residual disease correctly?
    Leukemia. 2024;38:219-220.
    >> Share

  411. RADIVOYEVITCH T, Gale RP, Kalaycio ME
    What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
    Leukemia. 2024;38:207-209.
    >> Share

  412. GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al
    A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
    Leukemia. 2024;38:58-66.
    >> Share

  413. YAN M, Liu M, Davis AG, Stoner SA, et al
    Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
    Leukemia. 2024;38:31-44.
    >> Share

    December 2023
  414. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117.
    >> Share

  415. YANADA M, Yamasaki S, Kondo T, Kawata T, et al
    Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119.
    >> Share

  416. MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al
    The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109.
    >> Share

  417. DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al
    Backtracking to the future: unraveling the origins of childhood leukemia.
    Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111.
    >> Share

  418. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    Correction: A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112.
    >> Share

  419. MURPHY T, Mason JM, Leber B, Bray MR, et al
    Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110.
    >> Share

  420. HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al
    Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
    Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102.
    >> Share

  421. KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al
    Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
    Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104.
    >> Share

  422. TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al
    ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
    Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103.
    >> Share

  423. SABA L, Landau KS, Liang H, Fu CL, et al
    Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.
    Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100.
    >> Share

  424. ANTIC Z, van Bommel A, Riege K, Lentes J, et al
    Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL.
    Leukemia. 2023;37:2522-2525.
    >> Share

  425. SCHIFFER CA
    Glasdigib fails to slay the hedgehog in pivotal AML trials.
    Leukemia. 2023;37:2520-2521.
    >> Share

  426. BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al
    Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
    Leukemia. 2023;37:2517-2519.
    >> Share

  427. XIANG J, Devenport JM, Carter AJ, Staser KW, et al
    An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
    Leukemia. 2023;37:2448-2456.
    >> Share

    November 2023
  428. MILIARA S, Cozzi E, Zhong X, Chan I, et al
    The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia.
    Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098.
    >> Share

  429. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
    Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
    >> Share

  430. OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al
    Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068.
    >> Share

  431. ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al
    Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080.
    >> Share

  432. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096.
    >> Share

  433. LEUNG KT, Cai J, Liu Y, Chan KYY, et al
    Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089.
    >> Share

  434. ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al
    Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
    Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083.
    >> Share

  435. WALTER RB
    Perspective on measurable residual disease testing in acute myeloid leukemia.
    Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084.
    >> Share

  436. WU Y, Zehnle PMA, Rajak J, Koleci N, et al
    BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079.
    >> Share

  437. ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al
    PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041.
    >> Share

  438. TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al
    High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
    Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075.
    >> Share

  439. HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al
    Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074.
    >> Share

  440. WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al
    Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077.
    >> Share

  441. FALINI B, Gjertsen BT, Andresen V
    The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
    Leukemia. 2023;37:2173-2175.
    >> Share

  442. LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al
    Survival with chronic myeloid leukaemia after failing milestones.
    Leukemia. 2023;37:2231-2236.
    >> Share

  443. DU W, Xia Z, Luo Z, Chen Y, et al
    A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.
    Leukemia. 2023;37:2286-2291.
    >> Share

  444. BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al
    Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
    Leukemia. 2023;37:2209-2220.
    >> Share

  445. FENG Y, Qi S, Liu X, Zhang L, et al
    Have we been qualifying measurable residual disease correctly?
    Leukemia. 2023;37:2168-2172.
    >> Share

  446. LI S, Wang X, Liu L, Liu J, et al
    CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
    Leukemia. 2023;37:2176-2186.
    >> Share

    October 2023
  447. CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al
    ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
    Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076.
    >> Share

  448. BISCHOF L, Ussmann J, Grimm J, Bill M, et al
    Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072.
    >> Share

  449. V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al
    Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042.
    >> Share

  450. WU A, Yen R, Grasedieck S, Lin H, et al
    Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
    Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062.
    >> Share

  451. JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al
    Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057.
    >> Share

  452. DEL GIUDICE I, Foa R
    Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066.
    >> Share

  453. ECKARDT JN, Stasik S, Rollig C, Petzold A, et al
    Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
    Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061.
    >> Share

  454. OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al
    Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
    Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054.
    >> Share

  455. KANTARJIAN HM
    What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.
    Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053.
    >> Share

  456. TULKENS D, Boelens M, Naert T, Carron M, et al
    Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052.
    >> Share

  457. CROSS NCP, Ernst T, Branford S, Cayuela JM, et al
    European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048.
    >> Share

  458. JAHN E, Saadati M, Fenaux P, Gobbi M, et al
    Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
    Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017.
    >> Share

  459. HUBER S, Baer C, Hutter S, Dicker F, et al
    Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
    Leukemia. 2023;37:2138-2141.
    >> Share

  460. OTHMAN J, Potter N, Mokretar K, Taussig D, et al
    FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
    Leukemia. 2023;37:2066-2072.
    >> Share

  461. FISHER JG, Doyle ADP, Graham LV, Sonar S, et al
    XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
    Leukemia. 2023;37:2036-2049.
    >> Share

  462. CASERTA C, Nucera S, Barcella M, Fazio G, et al
    miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
    Leukemia. 2023;37:1994-2005.
    >> Share

  463. TIAN Z, Shi C, Yang G, Allen JK, et al
    Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
    Leukemia. 2023;37:2006-2016.
    >> Share

  464. GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al
    Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
    Leukemia. 2023;37:2115-2124.
    >> Share

    September 2023
  465. MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al
    mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043.
    >> Share

  466. JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al
    del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035.
    >> Share

  467. FECHINA L, Popov A, Tsaur G, Henze G, et al
    Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
    Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034.
    >> Share

  468. KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al
    Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
    Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029.
    >> Share

  469. DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al
    FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute myeloid leukemia.
    Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020.
    >> Share

  470. ECKARDT JN, Bill M, Rausch C, Metzeler K, et al
    Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.
    Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016